Clinical Trials for MTG4
| Topic | Trial name of investigational drug | Clinical Trial ID(s) | Status | OrphaCode | Link |
|---|---|---|---|---|---|
| Neuroendocrine Tumours | Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg (CLARINET FORTE) |
|
|
| |
| Neuroendocrine Tumors | Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumors (SPINET) |
|
|
| |
| Neuroendocrine Tumors | Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors. (ATLANT) |
|
|
| |
| Pheochromocytoma | PRESCRIPT - Phenoxybenzamine Versus Doxazosin in PCC Patients |
|
|
| |
| Pheochromocytoma and Paraganglioma | Multicenter Pheochromocytoma and Paraganglioma Evaluation (MUPPET) |
|
|
| |
| Pheochromocytoma and Paraganglioma | FIRSTMAPPP, Genetic variants associated with increased susceptibility to thyroid cancer |
|
|
| |
| Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumours | A study of MK-6482 Monotherapy in advanced Pheochromocytoma/Paraganglioma (PPGL) and pancreatic neuroendocrine tumors (pNET) |
|
|
| |
| PHTS tumour syndrome | INSPECT (Investigation into PHTS tumor syndrome) |
|
|
| |
| Neuroendocrine Tumours | Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) |
|
|
| |
| Gastro-enteropancreatic Neuroendocrine Tumor | A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in patients with, Grade 2 and Grade 3 advanced GEP-NET (NETTER-2 study) |
|
|
| |
| Multiple Endocrine Neoplasia Type 1 | PRIME Precision Radiotherapy Using MR-linac for Pancreatic Neuroendocrine Tumours in MEN1 Patients |
|
|
| |
| Neuroendocrine Tumors | A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somato-statin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET). |
|
|
| |
| Pheochromocytoma/Paraganglioma, pancreatic neuroendocrine tumors | A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET) |
|
|
| |
| Topic | Trial name of investigational drug | Clinical Trial ID(s) | Status | OrphaCode | Link |
Last update: May 19, 2022 on 11:02
An overview of all Clinical Trials can be found here.